Literature DB >> 26163875

Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia.

Alp Üçok1, Uğur Çikrikçili, Sercan Karabulut, Ada Salaj, Meliha Öztürk, Öznur Tabak, Rümeysa Durak.   

Abstract

The aim of this retrospective chart-review study was to investigate the relationship between delayed commencement of clozapine and the level of response in treatment-resistant schizophrenia (TRS). We included 162 patients with schizophrenia who used clozapine. The mean delay until starting clozapine after fulfillment of the TRS criteria was 29 months. The delay was shorter in those who gained benefit from clozapine (P=0.04), those who were treated in a specialized psychosis outpatient unit (P=0.01), and in men (P=0.009), and it correlated with age (P<0.001). The delay in starting clozapine and the maximum clozapine dose were independent contributors toward the response to clozapine in the logistic regression analysis. Moreover, of those who gained considerable benefit from clozapine, the patients were younger (P=0.01), the duration of illness before clozapine treatment was shorter (P=0.001), and the numbers of adequate antipsychotic trials before the use of clozapine were fewer (P=0.05). Our findings suggest that efforts aimed at reducing the delay for starting clozapine may increase the effectiveness of clozapine in TRS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26163875     DOI: 10.1097/YIC.0000000000000086

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  17 in total

1.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

2.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

3.  Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

Authors:  Elias Wagner; John M Kane; Christoph U Correll; Oliver Howes; Dan Siskind; William G Honer; Jimmy Lee; Peter Falkai; Thomas Schneider-Axmann; Alkomiet Hasan
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

4.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

Review 5.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

Review 6.  Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.

Authors:  Hiroshi Komatsu; Goh Onoguchi; Stefan Jerotic; Nobuhisa Kanahara; Yoshihisa Kakuto; Takashi Ono; Shunichi Funakoshi; Takeshi Yabana; Toru Nakazawa; Hiroaki Tomita
Journal:  Mol Psychiatry       Date:  2022-05-02       Impact factor: 15.992

7.  Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine.

Authors:  Xiaoping Yuan; Song Wang; Yudong Shi; Yating Yang; Yulong Zhang; Lei Xia; Kai Zhang; Huanzhong Liu
Journal:  Psychopharmacology (Berl)       Date:  2022-01-26       Impact factor: 4.530

8.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

Review 9.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

Review 10.  Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.

Authors:  Dolores Keating; Stephen McWilliams; Ian Schneider; Caroline Hynes; Gráinne Cousins; Judith Strawbridge; Mary Clarke
Journal:  BMJ Open       Date:  2017-01-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.